Anti-HIV activity of amphotericin B-cholesteryl sulfate colloidal dispersion in vitro

被引:20
作者
Konopka, K
Guo, LSS
Düzgünes, N
机构
[1] Univ Pacific, Sch Dent, Dept Microbiol, San Francisco, CA 94115 USA
[2] Sequus Pharmaceut Inc, Menlo Park, CA 94025 USA
关键词
amphotericin B; amphotericin B colloidal dispersion; human immunodeficiency virus (HIV); liposomes; sterically stabilized liposomes; antivirals;
D O I
10.1016/S0166-3542(99)00028-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined whether the anti-HIV-l activity of the polyene antibiotic Amphotericin B (AMB) is retained following incorporation into sterically stabilized 'Stealth' liposomes (L-AMB) with prolonged circulation in vivo, or cholesteryl sulfate colloidal dispersions (CD-AMB). The effects of the different preparations on acute infection of H9 cells with HIV-1(IIIB), spreading of the virus from chronically infected H9/HTLV-IIIB cells to SupT1 cells, and HIV-l-induced syncytium formation were evaluated. Infection was monitored by p24 levels in culture supernatants. L-AMB did not affect HIV-I infection. When present only during initial infection, AMB (3-20 mu g/ml) reduced p24 levels by 70-80% after 7 and 10 days post-infection, while CD-AMB inhibited p24 production by similar to 30-40% at day 7 and 50-60% at day 10. The inhibitory effect of CD-AMB and AMB was enhanced by continuous treatment of acutely infected cells. The reduction of p24 production during continuous treatment was not due to cytotoxicity. During spreading of infection from infected to uninfected cells, AMB almost completely inhibited virus production while CD-AMB reduced both p24 production and the cytopathic effect in a dose-dependent manner. HIV-I induced syncytium formation was slightly inhibited by AMB but not by CD-AMB. Because CD-AMB is considerably less cytotoxic than AMB, its ability to inhibit HIV infection in vivo needs to be evaluated further. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:197 / 209
页数:13
相关论文
共 56 条
[31]  
KONOPKA K, 1998, ANTIVIR RES, V37, P63
[32]   FUSION OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CELLS WITH UNINFECTED CELLS [J].
LIFSON, JD .
METHODS IN ENZYMOLOGY, 1993, 221 :3-12
[33]   TREATMENT AND PROPHYLAXIS OF DISSEMINATED INFECTION DUE TO CANDIDA-ALBICANS IN MICE WITH LIPOSOME-ENCAPSULATED AMPHOTERICIN-B [J].
LOPEZBERESTEIN, G ;
MEHTA, R ;
HOPFER, RL ;
MILLS, K ;
KASI, L ;
MEHTA, K ;
FAINSTEIN, V ;
LUNA, M ;
HERSH, EM ;
JULIANO, R .
JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (05) :939-945
[34]   In vitro determination of antiviral activity of MSS209, a new amphotericin B derivative, against primary isolates of HIV1 [J].
MagierowskaJung, M ;
Cefai, D ;
Marrakchi, H ;
Chieze, F ;
Agut, H ;
Huraux, JM ;
Seman, M .
RESEARCH IN VIROLOGY, 1996, 147 (05) :313-318
[35]   HIV-2 AND SIV INFECTION OF NONPRIMATE CELL-LINES EXPRESSING HUMAN CD4 - RESTRICTIONS TO REPLICATION AT DISTINCT STAGES [J].
MCKNIGHT, A ;
CLAPHAM, PR ;
WEISS, RA .
VIROLOGY, 1994, 201 (01) :8-18
[36]   ANTI-FUNGAL AGENTS USEFUL IN THERAPY OF SYSTEMIC FUNGAL-INFECTIONS [J].
MEDOFF, G ;
BRAJTBURG, J ;
KOBAYASHI, GS ;
BOLARD, J .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1983, 23 :303-330
[37]   ANTILEISHMANIAL ACTIVITY OF AMPHOTERICIN AND OTHER ANTIFUNGAL AGENTS ENTRAPPED IN LIPOSOMES [J].
NEW, RRC ;
CHANCE, ML ;
HEATH, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1981, 8 (05) :371-381
[38]  
Norman A W, 1976, Adv Lipid Res, V14, P127
[39]   ANTI-HIV-1 ACTIVITY OF SULFATED AMPHOTERICIN-B INVITRO [J].
OTAKE, T ;
MIYANO, K ;
MORI, H ;
MORIMOTO, M ;
UEBA, N ;
KUNITA, N ;
NAKASHIMA, H ;
KURIMURA, T .
ANTIVIRAL RESEARCH, 1991, 16 (03) :243-255
[40]   ECOTROPIC MURINE LEUKEMIA VIRUS-INDUCED FUSION OF MURINE CELLS [J].
PINTER, A ;
CHEN, TE ;
LOWY, A ;
CORTEZ, NG ;
SILAGI, S .
JOURNAL OF VIROLOGY, 1986, 57 (03) :1048-1054